阿仑膦酸钠联合钙尔奇D对糖尿病性骨质疏松症患者骨密度和骨代谢指标影响及疗效观察.docxVIP

阿仑膦酸钠联合钙尔奇D对糖尿病性骨质疏松症患者骨密度和骨代谢指标影响及疗效观察 [Abstract] Objective To investigate the effect of alendronate sodium combined with Caltrate D on bone mineral density and bone metabolism in patients with diabetic osteoporosis and efficacy observation. Methods 90 cases of type 2 diabetic osteoporosis in the hospital from January 2017 to April 2018 were enrolled. The patients were randomLy divided into observation group （n=45） and control group （n=45）. Both groups of patients were given oral hypoglycemic drugs or insulin to control blood sugar， and also given Caltrate D 600 mg/time， 1 time/d， oral before meals. The observation group was treated with alendronate sodium 70 mg/time， once a week， orally， for 6 months. Changes in the levels of bone mineral density， serum bone metabolism index （molecular fragment of osteocalcin N-terminus） and bone-specific alkaline phosphatase （BALP） before treatment and at 6 months after treatment， and their clinical efficacy was compared. Results After 6 months of treatment， the bone mineral density of the femoral neck， femur trochanter and Fahrenheit triangle were significantly improved（P0.05 or P0.01）. And the improvement of observation group was more obvious than that of the control group （P0.05）. The serum N-MID index of the two groups was better than that before （P0.05）. BALP indicator was significantly lower than that before（P0.05 or P0.01）. And the change of the observation group was better than that of the control group （P0.05）. At the same time， the clinical total effective rate of the observation group（95.56%） was significantly higher than that of the control group（82.22%） （χ2=4.05， P0.05）. Conclusion Lendronate sodium combined with Caltrate D in the treatment of diabetic osteoporosis has exact efficacy， which can significantly improve the pain symptoms， increase its bone density value. The mechanism of action may be closely related to its ability to raise serum N-MID， reduce BALP， inhibit bone resorption and promote bone formation.